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Figure 1. Fluoroscopy and echocardiography; A. Severe aortic bioprosthesis 
stenosis; B. Corevalve positioned at bioprosthesis level. Visible bioprosthetic 
ring (white arrow); C. Partially released Corevalve prosthesis (white arrow). 
Inappropriate position over bioprosthetic ring; D. Recaptured Corevalve 
prosthesis; E. Early phase of second deployment; F. Corevalve completely 
released; G. Visible Corevalve prosthesis in left ventricular outflow track  
and ascending aorta (white arrows)
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A 72-year-old woman with a history of aortic valve replacement with a 21 mm Sorin Pericarbon More bioprosthetic valve 
(Sorin, Sallugia, Italy) associated with coronary artery bypass grafting (left internal mammary artery-left anterior descending 
artery [LIMA-LAD], aorta-right coronary artery [Ao-RCA]) in 2007 was admitted to our hospital on account of recurrent 
symptoms of congestive heart failure NYHA class III. Her medical history was significant for arterial hypertension, diabetes 
and renal insufficiency with an estimated glomerular filtration rate of 40 mL/min. Echocardiography revealed a degener-
ated aortic bioprosthesis with maximal and mean pressure gradients of 133 and 73 mm Hg, respectively and a calculated 
aortic valve area of 0.5 cm2 with a depressed left ventricular ejection fraction of 40% (Fig. 1A). Coronary angiography 
revealed significant stenosis of LAD and RCA; the LIMA and Ao-RCA grafts were patent. Peripheral angiography dem-
onstrated wide iliac and common femoral arteries (CFA) suitable for transcatheter aortic valve replacement (TAVI). Risk 
scores were calculated: Euroscore II was 14% and STS mortality score was 22%. Taking into account the high surgical risk, 
the Heart Team decided to perform a valve-in-valve TAVI. The procedure was performed on 4 November 2014 under 
general anaesthesia. The right CFA was surgically exposed. After placing a pigtail catheter in the ascending aorta via the 
left CFA artery, the right CFA was punctured 
and 12-F sheath was initially used to insert 
a stiff guidewire into the left ventricle through 
the degenerated bioprosthesis. We decided 
to use a new generation Corevalve Evolut R 
prosthesis (Medtronic, Minneapolis, MN, 
USA) which has a lower delivery profile 
equivalent to a 14 Fr system and offers the 
option to recapture and reposition during the 
deployment phase, if needed. The Corevalve 
Evolut R 23 mm was inserted and positioned 
at aortic bioprosthesis level (Fig. 1B). The 
fluoroscopically visible bioprosthetic ring 
facilitated the identification of the best 
radiographic projection. During the first at-
tempt, the prosthesis was positioned too high 
(Fig. 1C). The valve was easily recaptured 
in the ascending aorta and implanted once 
again in the optimal position with excellent 
angiographic and echocardiographic results 
(Fig. 1D–G). Further in-hospital course was 
uneventful, and the patient was discharged 
on the seventh day after TAVI.
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